E-therapeutics announced positive preclinical toxicology data on ETX-312, its therapy for people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver…
Six months of treatment with lanifibranor, Inventiva’s experimental therapy, reduced abnormalities in liver sinusoidal endothelial cells (LSECs) in people with metabolic dysfunction-associated steatohepatitis (MASH),…
Biliary atresia, a rare liver disease affecting infants, may be diagnosed before birth using a novel artificial intelligence (AI) method that analyzes prenatal ultrasound…
Combining the levels of two liver damage markers, obtained from standard blood tests, can accurately discriminate infants with biliary atresia from those without the…
The use of an experimental, one-time gene therapy in a mouse model of Alagille syndrome increased the number of bile ducts — tubes that…
The cumulative healthcare costs for infants with biliary atresia can increase substantially if they undergo their initial treatment, the Kasai surgery, after 2 months…
ACER3, an enzyme involved in the metabolism of fat-like signaling molecules known as ceramides, plays a detrimental role in cholestasis-related liver damage — and,…
Despite the established link between a younger age at standard Kasai surgery and better outcomes for infants with biliary atresia, the time between the…
A new artificial intelligence (AI) model based on clinical data along with laboratory results and ultrasound images aids the early diagnosis of biliary atresia,…
Severe mutations in the ABCB11 gene cause progressive familial intrahepatic cholestasis type 2 (PFIC2) by destabilizing the resulting BSEP protein in a specific region,…
